We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Intrexon (XON) Q4 Loss Narrower Than Expected, Revenues Beat
Read MoreHide Full Article
Intrexon Corporation reported adjusted loss of 17 cents per share in the fourth quarter of 2017, which was narrower than the Zacks Consensus Estimate of a loss of 31 cents.
Total revenues came in at $77 million, up 67.4% year over year. Reported revenues beat the Zacks Consensus Estimate of $49 million.
Over an year, the stock declined 45.2%, as against the industry’s gain of 0.1%.
Quarter in Detail
Intrexon’s sales primarily consist of collaboration and licensing revenues as well as product and service revenues.
Collaboration and licensing revenues increased significantly by 102.7% to $56.2 million year over year. The increase was due to the recognition of previously deferred revenue totaling $28.9 million related to the company's collaboration with ZIOPHARM for the treatment of graft-versus-host disease. The collaboration was however mutually terminated in December 2017.
While product revenues came in at $7.8 million, up 1.5% from the year-ago period, service revenues amounted to $12.7 million, up 23.3% year over year.
Intrexon follows a business model under which it commercializes its technologies through exclusive channel collaborations (ECC), licensing agreements and joint ventures with collaborators that have market and product development expertise as well as sales and marketing capabilities to bring new and improved products and processes to market. Such agreements provide the company with funds in the form of technology access fees along with milestones and other payments.
Meanwhile, the company is developing several candidates in partnership with other companies.
Intrexon’s collaborator, ZIOPHARM, announced the dosing of first patient in a new phase I study of its gene therapy Ad-RTS-hIL-12 + veledimex for the treatment of pediatric brain tumors.
Furthermore, the company’s collaborator Fibrocell Science, Inc. obtained allowance from the FDA to commence enrollment of pediatric patients in the phase II portion of its phase I/II study of FCX-007, its gene therapy candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell also submitted an Investigational New Drug Application (IND) with the FDA for FCX-013, its gene therapy candidate for the treatment of moderate to severe localized scleroderma.
Intrexon structured its principal healthcare assets into two separate wholly owned subsidiaries – Precigen, Inc., a gene and cell therapy company developing precision medicines, and ActoBio Therapeutics, Inc., a company focused, via its proprietary ActoBiotics platform, on therapeutic delivery of biologics to the site of disease.
2017 Results
Revenue in 2017 amounted to $231 million, up 21% year over year. Results beat the Zacks Consensus Estimate of $202.7 million.
Intrexon Corporation Price, Consensus and EPS Surprise
Ligand’s earnings per share estimates have moved up $3.54 to $4.15 for 2018 over the last 30 days. The company pulled off positive earnings surprises in three of the trailing four quarters, with an average beat of 24.88%. The share price of the company has increased 51.6% over an year.
Don’t Even Think About Buying Bitcoin Until You Read This
The most popular cryptocurrency skyrocketed last year, giving some investors the chance to bank 20X returns or even more. Those gains, however, came with serious volatility and risk. Bitcoin sank 25% or more 3 times in 2017. Zacks has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
Image: Bigstock
Intrexon (XON) Q4 Loss Narrower Than Expected, Revenues Beat
Intrexon Corporation reported adjusted loss of 17 cents per share in the fourth quarter of 2017, which was narrower than the Zacks Consensus Estimate of a loss of 31 cents.
Total revenues came in at $77 million, up 67.4% year over year. Reported revenues beat the Zacks Consensus Estimate of $49 million.
Over an year, the stock declined 45.2%, as against the industry’s gain of 0.1%.
Quarter in Detail
Intrexon’s sales primarily consist of collaboration and licensing revenues as well as product and service revenues.
Collaboration and licensing revenues increased significantly by 102.7% to $56.2 million year over year. The increase was due to the recognition of previously deferred revenue totaling $28.9 million related to the company's collaboration with ZIOPHARM for the treatment of graft-versus-host disease. The collaboration was however mutually terminated in December 2017.
While product revenues came in at $7.8 million, up 1.5% from the year-ago period, service revenues amounted to $12.7 million, up 23.3% year over year.
Intrexon follows a business model under which it commercializes its technologies through exclusive channel collaborations (ECC), licensing agreements and joint ventures with collaborators that have market and product development expertise as well as sales and marketing capabilities to bring new and improved products and processes to market. Such agreements provide the company with funds in the form of technology access fees along with milestones and other payments.
Meanwhile, the company is developing several candidates in partnership with other companies.
Intrexon’s collaborator, ZIOPHARM, announced the dosing of first patient in a new phase I study of its gene therapy Ad-RTS-hIL-12 + veledimex for the treatment of pediatric brain tumors.
Furthermore, the company’s collaborator Fibrocell Science, Inc. obtained allowance from the FDA to commence enrollment of pediatric patients in the phase II portion of its phase I/II study of FCX-007, its gene therapy candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell also submitted an Investigational New Drug Application (IND) with the FDA for FCX-013, its gene therapy candidate for the treatment of moderate to severe localized scleroderma.
Intrexon structured its principal healthcare assets into two separate wholly owned subsidiaries – Precigen, Inc., a gene and cell therapy company developing precision medicines, and ActoBio Therapeutics, Inc., a company focused, via its proprietary ActoBiotics platform, on therapeutic delivery of biologics to the site of disease.
2017 Results
Revenue in 2017 amounted to $231 million, up 21% year over year. Results beat the Zacks Consensus Estimate of $202.7 million.
Intrexon Corporation Price, Consensus and EPS Surprise
Intrexon Corporation Price, Consensus and EPS Surprise | Intrexon Corporation Quote
Zacks Rank & Stock to Consider
Intrexon carries a Zacks Rank #3 (Hold).
A better-ranked health care stocks in the same space is Ligand Pharmaceuticals Incorporated (LGND - Free Report) carrying a Zacks Rank #2 (Buy), You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Ligand’s earnings per share estimates have moved up $3.54 to $4.15 for 2018 over the last 30 days. The company pulled off positive earnings surprises in three of the trailing four quarters, with an average beat of 24.88%. The share price of the company has increased 51.6% over an year.
Don’t Even Think About Buying Bitcoin Until You Read This
The most popular cryptocurrency skyrocketed last year, giving some investors the chance to bank 20X returns or even more. Those gains, however, came with serious volatility and risk. Bitcoin sank 25% or more 3 times in 2017. Zacks has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
See 4 crypto-related stocks now >>